N-Acetyl Selank (10mg) Research Peptide

Product Introduction

N-Acetyl Selank (10mg) is a modified synthetic peptide supplied by Core Peptides for laboratory and scientific research applications. Each vial contains 10mg of N-Acetyl Selank, providing researchers with a defined quantity of peptide material for controlled experimental studies.

N-Acetyl Selank is a chemically modified form of Selank, a synthetic peptide that has been investigated in scientific research involving peptide chemistry, molecular signaling, and cellular processes. The N-acetyl modification makes this peptide of interest for researchers studying how structural changes can affect peptide characteristics and behavior in experimental systems.

N-Acetyl Selank (10mg) is supplied with an emphasis on quality, consistency, and reliable laboratory use. It is intended exclusively for scientific research and is not intended for human or veterinary use.

What Is N-Acetyl Selank?

N-Acetyl Selank is a modified peptide related to Selank. Selank is a synthetic peptide sequence that has been investigated in various areas of scientific research, while N-acetylation introduces a chemical modification to the peptide structure.

Chemical modifications are commonly examined in peptide research because changes to a peptide’s structure can influence characteristics such as molecular interactions, stability, and behavior under experimental conditions.

Researchers can use N-Acetyl Selank (10mg) as a defined research material when investigating peptide structure, molecular interactions, biochemical processes, and related experimental questions.

N-Acetyl Selank Research Applications

N-Acetyl Selank may be relevant to research involving peptide chemistry, molecular biology, biochemical research, and cellular signaling. Laboratory investigations can examine peptide characteristics, molecular interactions, receptor-related research, and other mechanisms of interest.

Research applications depend on the specific experimental model and objectives of the laboratory. Researchers may employ analytical testing, biochemical assays, or controlled experimental systems to investigate the properties and behavior of N-Acetyl Selank.

The appropriate experimental concentration, methodology, controls, and handling procedures should be established by qualified researchers according to their laboratory protocols.

Product Specifications

Quality and Consistency

Reliable research depends on consistent laboratory materials. N-Acetyl Selank (10mg) is supplied with an emphasis on quality, consistency, and suitability for controlled scientific research.

Researchers should review available product and batch documentation when evaluating the material for a particular experiment. Appropriate analytical methods and laboratory controls should be used when assessing peptide materials within an experimental system.

Packaging and Handling

Each N-Acetyl Selank (10mg) product is securely packaged to help protect the research material during storage and transportation.

Researchers should follow applicable product documentation and established laboratory procedures for receiving, storage, handling, and preparation. Appropriate laboratory safety practices should always be followed when working with research peptides.

Why Choose Core Peptides?

Core Peptides provides research-focused peptide materials for laboratories, researchers, and scientific investigations. N-Acetyl Selank (10mg) gives researchers access to a defined quantity of modified Selank peptide for controlled experimental work.

Clear product identification, quantity information, research-use positioning, and secure packaging help researchers evaluate the material for their specific laboratory requirements.

Research Use Disclaimer

N-Acetyl Selank (10mg) is supplied strictly for laboratory and scientific research purposes. It is not approved or intended for human consumption, self-administration, diagnosis, treatment, prevention, or mitigation of any disease or medical condition. It is not intended for veterinary use. Researchers are responsible for complying with applicable laws, institutional requirements, laboratory safety standards, and appropriate handling procedures.

Product Features

• Contains 10mg of N-Acetyl Selank
• Modified synthetic peptide
• Research-grade laboratory material
• Suitable for peptide and molecular research
• Relevant to biochemical and cellular research
• Quality-focused production
• Securely packaged
• For research use only
• Not for human or veterinary use

References

1. T.A Kolomin et al., Transcriptomic Response of Rat Hippocampus and Spleen Cells to Single and Chronic Administration of the Peptide Selank. June 2, 2009.
2. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 11765600, Selank. https://pubchem.ncbi.nlm.nih.gov/compound/Selank
3. Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. Russian. https://pubmed.ncbi.nlm.nih.gov/25176261/
4. Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neurosci Behav Physiol. 2003 Sep;33(7):639-43. https://pubmed.ncbi.nlm.nih.gov/14552529/
5. Uchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA, Shcherbenko VE, Mezentseva MV, Gabaeva MV, Sokolov OIu, Zozulia AA, Ershov FI. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-5. Russian. https://pubmed.ncbi.nlm.nih.gov/18577961/
6. Kolik LG, Nadorova AV, Kozlovskaya MM. Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Bull Exp Biol Med. 2014 May;157(1):52-5. https://pubmed.ncbi.nlm.nih.gov/24913576/
7. N.F. Mjasoedov et al, The Influence of Selank on the Parameters of the Hemostasis System, Lipid Profile, and Blood Sugar Level in the Course of Experimental Metabolic Syndrome. April 14, 2014.